Phaseline

Targets › ASL

ASL (Argininosuccinate lyase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Sep 2028.

Catalyzes the reversible cleavage of L-argininosuccinate to fumarate and L-arginine, an intermediate step reaction in the urea cycle mostly providing for hepatic nitrogen detoxification into excretable urea as well as de novo L-arginine synthesis in nonhepatic tissues. Essential regulator of intracellular and extracellular L-arginine pools. (UniProt, P04424)

Open in Phaseline: the race on ASL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rebecca Ahrens-NicklasLNP.UCD.ABE
adenine base editor (ABE) delivered by lipid nanoparticle (LNP) for urea cycle disorder ge
CPS1, OTC, ASS1, ASL, ARG1Phase 1Urea Cycle DisordersSep 2028

Conditions

Urea Cycle Disorders (1)

Modalities

protein or peptide (1)

Companies

Rebecca Ahrens-Nicklas (1)

Related targets

CPS1 (1) OTC (1) ASS1 (1) ARG1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.